CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis Drug-eluting balloons in coronary interventions: the quiet revolution? Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis
|<< 1 2 3 4 5 6 >>|

Clinical Trial2018 Jan 8. [Epub ahead of print]

JOURNAL：J Interv Cardiol. Article Link

Short-term and long-term clinical outcomes of rotational atherectomy in resistant chronic total occlusion

Huang WC, Teng HI, Chan WL et al. Keywords: calcification; chronic total occlusion; coronary artery disease; rotational atherectomy

ABSTRACT

OBJECTIVES - To evaluate the short- and long-term clinical outcomes of RA in CTO coronary intervention.


BACKGROUND - The application of rotational atherectomy (RA) may improve the success rate of percutaneous recanalization of chronic total occlusion (CTO) with heavy calcification.


METHODS - From January 2011 to September 2014, we enrolled 285 patients with CTO who underwent successful percutaneous coronary intervention (PCI). Resistant CTO lesions were defined as those with heavy calcifications as well as those that no devices are able to pass after guide wire crossing.


RESULTS - All patients with resistant CTO lesions (n = 26) were successfully treated by RA without major complications, except 1 patient complicated with coronary perforation and treated by surgery successfully (success rate: RA group vs non-RA group: 96.2%, vs 89.5%, P = 0.038). Compared to the non-RA group, the patients in the RA group were older (P = 0.028), had higher J-CTO scores (P = 0.001), and needed longer stents (P = 0.001). All patients were followed up for a mean period of 3.4 ± 2.3 years, and the 1-year and long-term clinical outcomes of the RA group were excellent and comparable with those not receiving RA in multivariate analysis adjusted for multiple variables.


CONCLUSION - The treatment of RA is safe and feasible for resistant CTO lesions with heavy calcification. The short- and long-term clinical outcomes of the treatment of RA were excellent and comparable with those not needing RA for CTO PCI.


© 2018, Wiley Periodicals, Inc.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top